ReviewApoptosis : an international journal on programmed cell death2026
Ferroptosis and its role in immune modulation in breast cancer.
Review in Apoptosis : an international journal on programmed cell death, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Programmed cell death and metastatic evolution in breast cancer: the role of anoikis, necroptosis, and ferroptosis.Apoptosis : an international journal on programmed cell death · 2026Review
- NUPR1 in breast cancer: mechanisms and potential applications.Frontiers in physiology · 2026Review
- Targeting glutathione peroxidase 4 in ferroptosis: from immune regulation to pharmacological development and translational applications.Frontiers in pharmacology · 2026Review
- Polyphyllin B induces ferroptosis in triple-negative breast cancer by inactivating NRF2.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Iron-catalyzed lipid peroxidation, a hallmark of the regulated cell death (RCD) known as ferroptosis, has gained prominence in cancer biology, and its application in anticancer treatments is gaining attention. Triggering ferroptosis may curtail the advancement of tumorigenesis, offer opportunities to boost immunotherapy outcomes, and overcome resistance to established oncological interventions. Nevertheless, the function of ferroptosis in immune modulation has not been systematically addressed, particularly in breast carcinoma. This review explores the molecular basis of ferroptosis and discusses the therapeutic implications, particularly in breast carcinoma. Moreover, the complex interrelationship between ferroptosis and immune modulation has been examined, spotlighting how ferroptotic tumor cells can impact simultaneous tumor-suppressive and tumor-promoting immune activities in the breast cancer microenvironment. Furthermore, the involvement of immune cells in regulating ferroptosis has been explored, highlighting the dual interaction dynamics between ferroptosis and immune functions. Additionally, the exploration includes the application of ferroptosis in breast carcinoma immunotherapy, proposing a promising avenue to boost therapeutic efficacy. Ultimately, grasping the bifunctional nature of ferroptosis in immune modulation unveils new perspectives for pioneering breast carcinoma therapies.
Indexed as
Identifiers
41553559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.